Literature DB >> 24761855

Hypofractionated radiotherapy for breast cancers--preliminary results from a tertiary care center in eastern India.

Moujhuri Nandi1, Anurupa Mahata, Indranil Mallick, Rimpa Achari, Sanjoy Chatterjee.   

Abstract

BACKGROUND: The standard radiotherapy (RT) fractionation practiced in India and worldwide is 50 Gy in 25 fractions over 5 weeks to the chest wall or whole breast followed by tumour bed boost in case of breast conservation (BCS). A body of validated data exists regarding hypofractionation in breast cancer. We here report initial results for 135 patients treated at our center with the START-B type of fractionation.
MATERIALS AND METHODS: From May 2011 till July 2012, women with all stages of breast cancer (excluding metastatic), who had undergone BCS or mastectomy were planned for 40 Gy in 15 fractions over 3 weeks to chest wall/whole breast and supraclavicular fossa (where indicated) followed by tumour bed boost in BCS patients. Planning was done using Casebow's technique. The primary end point was to assess the acute toxicity and the cosmetic outcomes. Using cosmetic scales; patients were assessed during radiotherapy and at subsequent follow up visits with the radiation oncologist.
RESULTS: Of the 135 patients, 62 had undergone BCS and 73 mastectomy. Median age of the population was 52 years. Some 80% were T1 and T2 tumours in BCS whereas most patients in mastectomy group were T3 and T4 tumours (60%). 45% were node negative in BCS group whilst it was 23% in the mastectomy group. Average NPI scores were 3.9 and 4.9, respectively. Most frequently reported histopathology report was infiltrating ductal carcinoma (87%), grade III being most common (58%), and 69% were ER positive tumours, and 30% were Her 2 Neu positive. Triple negative tumours accounted for 13% and their mean age was young (43 yrs.) The maximum acute skin toxicity at the end of treatment was Grade 1 in 94% of the mastectomy group patients and 71% in BCS patients. Grade 2 toxicity was 6% in mast group and 23% in BCS group. Grade 3 was 6% in BCS group, no grade 3 toxicity in mastectomy patients and there was no grade 4 skin toxicity in any case. Post RT at 1 month; 39% of BCS patients had persisting Grade I skin reaction which was only 2% in mastectomy patients. At 3 months post RT, 18% patients had persisting hyperpigmentation. At 6 months 8% patients had persisting erythema in the BCS group only. Some 3% BCS and 8% mastectomy patients had lymph edema till the date of evaluation. Cosmetic outcome in BCS patients remained good to excellent 6 months post surgery and radiotherapy. 1 patient of BCS and 3 patients of mast had developed metastatic disease at the time of evaluation.
CONCLUSIONS: Hypofractionated RT is well tolerated in Indian population with reduced acute skin toxicity and good cosmetic outcome. Regimens such as these should be encouraged in other centers to increase machine output time. The study is on-going to assess long term results.

Entities:  

Mesh:

Year:  2014        PMID: 24761855     DOI: 10.7314/apjcp.2014.15.6.2505

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  11 in total

1.  A Study on Dosimetric Outcomes and Acute Toxicity of Post Mastectomy Adjuvant Hypofractionated Radiotherapy for Breast Cancer.

Authors:  Shivaprasad Deshmukh; Krishna Sharan; Donald Jerard Fernandes; Vidyasagar Mamidipudi Srinivasa; Prahlad Hiremagalur Yathiraj; Anshul Singh; Anusha Reddy
Journal:  J Clin Diagn Res       Date:  2016-07-01

Review 2.  Prevalence of Molecular Subtypes of Breast Cancer in India: a Systematic Review and Meta-analysis.

Authors:  Pavan Kumar Jonnada; Cherukuru Sushma; Madhuri Karyampudi; Anvesh Dharanikota
Journal:  Indian J Surg Oncol       Date:  2020-10-28

Review 3.  Breast cancer: An overview of published Indian data.

Authors:  Bharath Rangarajan; Tanuja Shet; Tabassum Wadasadawala; Nita S Nair; R Madhu Sairam; Sachin S Hingmire; Jyoti Bajpai
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep

4.  Immunohistochemistry Heterogeneity in Reported Breast Cancer Demographics From India: Triple-Negative Breast Cancer Rates Could Be Lower Than Suggested in Pooled Meta-Analysis.

Authors:  Sanjoy Chatterjee; Indu Arun; Sanjit Agrawal; Moses Arunsingh; Indranil Mallick; Rosina Ahmed
Journal:  J Glob Oncol       Date:  2016-09-07

Review 5.  Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis.

Authors:  Gurprataap S Sandhu; Sebhat Erqou; Heidi Patterson; Aju Mathew
Journal:  J Glob Oncol       Date:  2016-06-29

6.  Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer.

Authors:  Apurv Kulkarni; Devaki A Kelkar; Nidhi Parikh; Lingadahalli S Shashidhara; Chaitanyanand B Koppiker; Madhura Kulkarni
Journal:  JCO Glob Oncol       Date:  2020-07

7.  Prevalence and incidence of cancer related lymphedema in low and middle-income countries: a systematic review and meta-analysis.

Authors:  Eric Torgbenu; Tim Luckett; Mark A Buhagiar; Sungwon Chang; Jane L Phillips
Journal:  BMC Cancer       Date:  2020-06-29       Impact factor: 4.430

8.  Feasibility, Tolerance, and Quality of Life for Hypofractionation Versus Conventional Fractionation for Post-mastectomy Radiotherapy in Indian Patients.

Authors:  Deepika Malik; Ashok Singh; Manoj M Birajdar; Virendra J Vyas
Journal:  Cureus       Date:  2022-03-25

Review 9.  Awareness and current knowledge of breast cancer.

Authors:  Muhammad Akram; Mehwish Iqbal; Muhammad Daniyal; Asmat Ullah Khan
Journal:  Biol Res       Date:  2017-10-02       Impact factor: 5.612

10.  Practical consensus recommendations regarding role of postmastectomy radiation therapy.

Authors:  D Singh; G Saini; R Koul; V Gupta; D Abrol; S De; P Kulshrestha; S N Hukku; S J Lakshmi; Purvish M Parikh; S Aggarwal
Journal:  South Asian J Cancer       Date:  2018 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.